Behzad Hajarizadeh1, Bart Grady2, Kimberly Page3, Arthur Y Kim4, Barbara H McGovern5, Andrea L Cox6, Thomas M Rice3, Rachel Sacks-Davis7, Julie Bruneau8, Meghan Morris3, Janaki Amin9, Janke Schinkel10, Tanya Applegate9, Lisa Maher9, Margaret Hellard7, Andrew R Lloyd11, Maria Prins12, Ronald B Geskus12, Gregory J Dore9, Jason Grebely9. 1. The Kirby Institute, UNSW Australia, Sydney, NSW, Australia. Electronic address: bhajarizadeh@kirby.unsw.edu.au. 2. Cluster Infectious Diseases, GGD Public Health Service of Amsterdam, Amsterdam, The Netherlands. 3. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA. 4. Harvard Medical School, Boston, MA, USA. 5. Tufts Medical School, Boston, MA, USA; Abbvie, Chicago, IL, USA. 6. Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD, USA. 7. Burnet Institute, Melbourne, VIC, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia. 8. CRCHUM, Université de Montréal, Montreal, QC, Canada. 9. The Kirby Institute, UNSW Australia, Sydney, NSW, Australia. 10. Academic Medical Center, Amsterdam, The Netherlands. 11. Inflammation and Infection Research Centre, School of Medical Sciences, UNSW Australia, Sydney, NSW, Australia. 12. Cluster Infectious Diseases, GGD Public Health Service of Amsterdam, Amsterdam, The Netherlands; Academic Medical Center, Amsterdam, The Netherlands.
Abstract
BACKGROUND AND OBJECTIVES: Hepatitis C virus (HCV) RNA level in acute HCV infection is predictive of spontaneous clearance. This study assessed factors associated with HCV RNA levels during early acute infection among people who inject drugs with well-defined acute HCV infection. STUDY DESIGN: Data were from International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC(3)) Study, an international collaboration of nine prospective cohorts studying acute HCV infection. Individuals with available HCV RNA levels during early acute infection (first two months following infection) were included. The distribution of HCV RNA levels during early acute infection were compared by selected host and virological factors. RESULTS: A total of 195 individuals were included. Median HCV RNA levels were significantly higher among individuals with interferon lambda 3 (IFNL3, formerly called IL28B) CC genotype compared to those with TT/CT genotype (6.28 vs. 5.39logIU/mL, respectively; P=0.01). IFNL3 CC genotype was also associated with top tertile HCV RNA levels (≥6.3log IU/mL; vs. TT/CT genotype; adjusted Odds Ratio: 4.28; 95%CI: 2.01, 9.10; P<0.01). CONCLUSIONS: This study indicates that IFNL3 CC genotype predicts higher HCV RNA levels in early acute HCV infection.
BACKGROUND AND OBJECTIVES:Hepatitis C virus (HCV) RNA level in acute HCV infection is predictive of spontaneous clearance. This study assessed factors associated with HCV RNA levels during early acute infection among people who inject drugs with well-defined acute HCV infection. STUDY DESIGN: Data were from International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC(3)) Study, an international collaboration of nine prospective cohorts studying acute HCV infection. Individuals with available HCV RNA levels during early acute infection (first two months following infection) were included. The distribution of HCV RNA levels during early acute infection were compared by selected host and virological factors. RESULTS: A total of 195 individuals were included. Median HCV RNA levels were significantly higher among individuals with interferon lambda 3 (IFNL3, formerly called IL28B) CC genotype compared to those with TT/CT genotype (6.28 vs. 5.39logIU/mL, respectively; P=0.01). IFNL3 CC genotype was also associated with top tertile HCV RNA levels (≥6.3log IU/mL; vs. TT/CT genotype; adjusted Odds Ratio: 4.28; 95%CI: 2.01, 9.10; P<0.01). CONCLUSIONS: This study indicates that IFNL3 CC genotype predicts higher HCV RNA levels in early acute HCV infection.
Authors: D L Thomas; J Astemborski; R M Rai; F A Anania; M Schaeffer; N Galai; K Nolt; K E Nelson; S A Strathdee; L Johnson; O Laeyendecker; J Boitnott; L E Wilson; D Vlahov Journal: JAMA Date: 2000-07-26 Impact factor: 56.272
Authors: Behzad Hajarizadeh; Jason Grebely; Tanya Applegate; Gail V Matthews; Janaki Amin; Kathy Petoumenos; Margaret Hellard; William Rawlinson; Andrew Lloyd; John Kaldor; Gregory J Dore Journal: J Med Virol Date: 2014-07-08 Impact factor: 2.327
Authors: Jason Grebely; Kimberly Page; Rachel Sacks-Davis; Maarten Schim van der Loeff; Thomas M Rice; Julie Bruneau; Meghan D Morris; Behzad Hajarizadeh; Janaki Amin; Andrea L Cox; Arthur Y Kim; Barbara H McGovern; Janke Schinkel; Jacob George; Naglaa H Shoukry; Georg M Lauer; Lisa Maher; Andrew R Lloyd; Margaret Hellard; Gregory J Dore; Maria Prins Journal: Hepatology Date: 2013-11-22 Impact factor: 17.425
Authors: Andrea L Cox; Dale M Netski; Timothy Mosbruger; Susan G Sherman; Steffanie Strathdee; Danielle Ompad; David Vlahov; David Chien; Venkatakrishna Shyamala; Stuart C Ray; David L Thomas Journal: Clin Infect Dis Date: 2005-03-03 Impact factor: 9.079
Authors: Lorenzo Uccellini; Fan-Chen Tseng; Alessandro Monaco; Fatma M Shebl; Ruth Pfeiffer; Myhanh Dotrang; Dianna Buckett; Michael P Busch; Ena Wang; Brian R Edlin; Francesco M Marincola; Thomas R O'Brien Journal: Hepatology Date: 2012-06-01 Impact factor: 17.425
Authors: Harald Hofer; Thomas Watkins-Riedel; Oskar Janata; Edward Penner; Heidemarie Holzmann; Petra Steindl-Munda; Alfred Gangl; Peter Ferenci Journal: Hepatology Date: 2003-01 Impact factor: 17.425
Authors: Charlotte H B S van den Berg; Bart P X Grady; Janke Schinkel; Thijs van de Laar; Richard Molenkamp; Robin van Houdt; Roel A Coutinho; Debbie van Baarle; Maria Prins Journal: PLoS One Date: 2011-11-15 Impact factor: 3.240
Authors: Ramy El-Diwany; Lisa N Wasilewski; Kenneth W Witwer; Justin R Bailey; Kimberly Page; Stuart C Ray; Andrea L Cox; David L Thomas; Ashwin Balagopal Journal: J Virol Date: 2015-07-08 Impact factor: 5.103
Authors: B Hajarizadeh; B Grady; K Page; A Y Kim; B H McGovern; A L Cox; T M Rice; R Sacks-Davis; J Bruneau; M Morris; J Amin; J Schinkel; T Applegate; L Maher; M Hellard; A R Lloyd; M Prins; R B Geskus; G J Dore; J Grebely Journal: J Viral Hepat Date: 2015-01-08 Impact factor: 3.728
Authors: Behzad Hajarizadeh; Bart Grady; Kimberly Page; Arthur Y Kim; Barbara H McGovern; Andrea L Cox; Thomas M Rice; Rachel Sacks-Davis; Julie Bruneau; Meghan Morris; Janaki Amin; Janke Schinkel; Tanya Applegate; Lisa Maher; Margaret Hellard; Andrew R Lloyd; Maria Prins; Gregory J Dore; Jason Grebely Journal: PLoS One Date: 2015-04-02 Impact factor: 3.240